Haloperidol/CYP 3A4 Inducers (mono deleted 12/26/2013)
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may not process haloperidol properly.
What might happen:
You may experience an increase or decrease in the beneficial effects of your medicines.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together, or if you stop taking your other medicine. If you experience any personality change contact your doctor. The dosages of your medicines may need to be adjusted.Your healthcare professionals may already be aware of this drug interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Haldol (haloperidol) US prescribing information. Ortho-McNeil-Janssen Pharmaceuticals, Inc. August, 2011.
2.Yasui-Furukori N, Kondo T, Mihara K, Suzuki A, Inoue Y, Kaneko S. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients. J Clin Psychopharmacol 2003 Oct;23(5):435-40.
3.Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 1999 Aug;19(4):310-5.
4.Iwahashi K, Miyatake R, Suwaki H, Hosokawa K, Ichikawa Y. The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Clin Neuropharmacol 1995 Jun;18(3):233-6.
5.Arana GW, Goff DC, Friedman H, Ornsteen M, Greenblatt DJ, Black B, Shader RI. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms?. Am J Psychiatry 1986 May;143(5):650-1.
6.Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry 1984 Feb;41(2):165-70.
7.Hirokane G, Someya T, Takahashi S, Morita S, Shimoda K. Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data. Ther Drug Monit 1999 Feb;21(1):82-6.
8.Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report. Psychopharmacology (Berl) 1994 Sep;116(1):115-6.
9.Kahn EM, Schulz SC, Perel JM, Alexander JE. Change in haloperidol level due to carbamazepine--a complicating factor in combined medication for schizophrenia. J Clin Psychopharmacol 1990 Feb;10(1):54-7.
10.Fast DK, Jones BD, Kusalic M, Erickson M. Effect of carbamazepine on neuroleptic plasma levels and efficacy. Am J Psychiatry 1986 Jan; 143(1):117-8.
11.Jann MW, Ereshefsky L, Saklad SR, Seidel DR, Davis CM, Burch NR, Bowden CL. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 1985 Apr;5(2):106-9.
12.Cohen D, Diemont WL. Deterioration of schizoaffective disorder due to an interaction between haloperidol and carbamazepine. Ned Tijdschr Geneeskd 2002 Oct 12;146(41):1942-4.
13.Kanter GL, Yerevanian BI, Ciccone JR. Case report of a possible interaction between neuroleptics and carbamazepine. Am J Psychiatry 1984 Sep;141(9):1101-2.
14.Brayley J, Yellowlees P. An interaction between haloperidol and carbamazepine in a patient with cerebral palsy. Aust N Z J Psychiatry 1987 Dec;21(4):605-7.
15.Kim YH, Cha IJ, Shim JC, Shin JG, Yoon YR, Kim YK, Kim JI, Park GH, Jang IJ, Woo JI, Shin SG. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients. J Clin Psychopharmacol 1996 Jun;16(3):247-52.
16.Takeda M, Nishinuma K, Yamashita S, Matsubayashi T, Tanino S, Nishimura T. Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis. Clin Neuropharmacol 1986;9(4):386-97.
17.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ DrugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.